Background
The evolution and spread of drug resistant pathogens presents a growing problem worldwide. The fact that virtually all anti-microbials lose efficacy over time because of the development and spread of resistance in the target organism could be greatly reduced by creating novel and affordable approaches to optimal drug delivery tools, by developing drugs that target critical host components essential to infection and disease, as well as drugs that target components of the pathogen that are implicated in disease rather than infection, or that are so highly constrained that resistant variants cannot be easily selected.